Ziopharm Oncology is Biotechnology in United States that focus on ZIOPHARM Oncology Inc business. Founded in 1998. They cover business area such as ZIOPHARM Oncology Inc, cancer therapy, hematological and solid tumor malignancy, cellular therapeutic, ziopharm, gene therapy system, its partner, Intrexon, collaborator, Texas, its product candidate, contractual arrangement, licensing partner.
1998
( 26 years old in 2024 )
ZIOPHARM Oncology Inc
-
1 First Avenue, Parris Building
Suite 34, Navy Yard Plaza
Boston, MA 02129
United States
Private
ZIOPHARM Oncology Inccancer therapyhematological and solid tumor malignancycellular therapeuticziopharmgene therapy systemits partnerIntrexoncollaboratorTexasits product candidatecontractual arrangementlicensing partner
* We use standard office opening hours in near Ziopharm Oncology's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Ziopharm Oncology is Biotechnology business from United States that founded in 1998 (26 years old in 2024), Ziopharm Oncology business is focusing on ZIOPHARM Oncology Inc.
Ziopharm Oncology headquarter office and corporate office address is located in 1 First Avenue, Parris Building Suite 34, Navy Yard Plaza Boston, MA 02129 United States.
Ziopharm Oncology was founded in United States.
In 2024, Ziopharm Oncology is currently focus on ZIOPHARM Oncology Inc sector.
Above is snippet of Google Trends for "ZIOPHARM Oncology Inc" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Ziopharm Oncology, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
